UNSPSC 51284032: Guamecycline dihydrochloride

This classification denotes a tetracycline antibiotic with the molecular formula C29H38N8O8.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DL609MM5I8, chemically known as 2-naphthacenecarboxamide, n-((4-(((aminoiminomethyl)amino)iminomethyl)-1-piperazinyl)methyl)-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, hydrochloride (1:2), (4s,4as,5as,6s,12as)-, but more generally known as guamecycline dihydrochloride, which bears US NIH Compound Identifier 5464418.

UNSPSC 51284032 Guamecycline dihydrochloride is a Commodity code that shows minimal recent state and local procurement activity directly aligned with its nominal pharmaceutical scope. The recent opportunities tagged under this code diverge substantially from guamecycline — a tetracycline-class antibiotic — and instead reflect broader medical supply, emergency response, and pharmacy benefit procurement. State and local issuing bodies soliciting under or near this code are pursuing naloxone and drug deactivation systems, emergency medical supplies for fire department rescue operations, and generic pharmaceutical contracting through multistate cooperative purchasing vehicles. The work spans health departments, fire departments, pharmacy benefit programs, and state procurement offices acting on behalf of multiple member jurisdictions.

Recent activity includes Seminole County, Florida's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually (posted June 30, 2026, due July 26, 2023); the City of Tampa's IFB for medical and first aid supplies — 169 line items including respiratory equipment, cardiac monitoring electrodes, endotracheal tubes, and medical consumables for the Fire Department Rescue Division, estimated at $700,000 and due March 13, 2026, with a certified Small Local Business Enterprise set-aside and 5 percent bid discount; the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP for generic multi-source pharmaceuticals and OTC products (due March 26, 2026) serving state and local government facilities across Minnesota and Oregon; and the Texas Health and Human Services Commission RFI (posted April 3, 2026) on direct-to-manufacturer prescription fulfillment capabilities. Geographic activity is concentrated in Florida, Texas, and the upper Midwest, with multistate cooperative purchasing extending the reach. The code shows no recent opportunities for guamecycline specifically; vendors should verify whether this code accurately reflects their product line or whether broader pharmaceutical commodity codes better align with actual state and local demand.